ACE and heart failure: A major recent advance in the treatment of heart failure has been the introduction of the combined angiotensin receptor and neprilysin inhibitor, sacubitril/valsartan, that proved superior to the angiotensin converting enzyme inhibitor enalapril in reducing the risks of deaths or hospitalization for heart failure [16].